implementation must be near, page-3

I keep reading this article and cannot believe the opportunities along with the revenue stream that it will open up.

Its been tested, beat all the contenders and is being used by a pharmaceutical company in Europe on one of its most successful drug products and commences towards the end 2010.
Also has CSIRO as a partner.

With a 5 year contract.



DataDot Technology Limited
ABN 54 091 908 726
Securities Exchange Announcement
Tuesday, 27 July 2010
Pharmaceutical Brand Protection Project
DataTraceDNA has been selected by a European Pharmaceutical company to
provide a brand protection solution for one of their most successful drug
products.
DataDot Technology Limited (ASX: DDT) is pleased to announce that its joint
venture DataTraceDNA Pty. Ltd. (DataTrace P/L) has been selected by a world ?
leading European pharmaceutical company to authenticate the entire production
volume of one of its most successful drug products.
A five year contract has now been signed by both parties. Final production testing is
underway in Europe currently with full implementation expected before the end of
2010. This marks the conclusion of a two year process during which DataTrace P/L
was required to submit to the most rigorous testing and due diligence program which
culminated in being chosen ahead of competing technologies.
The DataTraceDNA
? solution was chosen because of its high security, durability,
flexibility of application and ability to be future proof against any sophisticated
counterfeit attack. The forensic signatures being applied to packaging are invisible
and can only be identified using our portable digital reader, ?The Authenticator?.
DataTrace P/L is a 50/50 joint venture between DDT and the CSIRO. Greg
Twemlow, General Manager of DataTrace P/L, said "DataTrace P/L is operating in a
very competitive global market and this contract is solid proof that we have in our
DataTraceDNA? product a world-class technology that has important advantages in
certain fields. This contract demonstrates our capability to work in diverse industries
by providing strategic solutions to the protection of brand and intellectual property
the counterfeiting of which is a growing global business challenge.?
The market for Brand Protection solutions in the Pharmaceutical industry is growing
rapidly due to the expansion of counterfeit drug production which in some countries
has reached alarming levels.
About DataTraceDNA
DataTraceDNA Pty. Ltd. (DataTrace P/L) is in a 50/50 joint venture with the CSIRO
and DDT. DataTrace P/L offers a groundbreaking approach to counterfeit security
protection through microtechnology, called DataTraceDNA
?, a technology that is
invisibly embedded within the molecular structure of a manufactured product.
DataDot Technology Ltd is listed on the Australian Stock Exchange under the code
?DDT?. The Commonwealth Scientific and Industrial Research Organisation (CSIRO)
owned by the Australian Federal Government, is one of the top ranked research
institutions in the world and is a leader in the rapidly growing field of nanotechnology.
The technologies are supported by DDT?s worldwide verification database.